HIV-1 maturation occurs via temporally regulated proteolysis of the Gag and Gag-Pol polyproteins at specific sites, leading to formation of a functional HIV-1 core. We have recently shown that 3-0-{3',3'- dimethylsuccinyl}-betulinic acid (DSB) blocks HIV-1 replication through a novel mechanism of action. DSB specifically inhibits the final step in HIV-1 Gag processing-cleavage at the CA-p2 junction. Inhibition requires the drug to be present at the time of HIV-1 assembly, indicating its action at a late stage of replication. However, the compound does not exhibit activity against the HIV-1 protease (PR) in vitro using peptides or recombinant Gag protein as substrates. HIV-1 acquires partial resistance to DSB by missense mutations at the CA-p2 junction, and mutations in PR that render HIV-1 resistant to PR inhibitors confer little to no resistance to DSB. We hypothesize that DSB associates with the CA-p2 junction during HIV-1 assembly or maturation, resulting in delayed PR cleavage of this site. Here we propose to further define the mechanism and consequences of DSB action through two Specific Aims: (1) to identify the molecular target of DSB; and (2) to determine the spectrum of resistance of HIV-1 to DSB and the fitness cost associated with resistance. These studies will precisely define the HIV-1 target of DSB as a potent small-molecule inhibitor of HIV-1 replication, thus providing information that will guide the design of the next generation of HIV-1 maturation inhibitors. Because DSB is a promising antiviral therapy that is currently being developed by Panacos Pharmaceuticals, a comprehensive analysis of HIV-1 resistance to DSB will serve to inform the human efficacy trials of DSB that will likely be initiated in the near future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI062452-01A2
Application #
6947480
Study Section
Special Emphasis Panel (ZRG1-AARR-A (09))
Program Officer
Black, Paul L
Project Start
2005-04-01
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
1
Fiscal Year
2005
Total Cost
$353,500
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212